Interim analysis of an RCT in 85 patients with recurrent acute or chronic pancreatitis flares: simvastatin for 1 year did not reduce recurrence vs placebo (46.2% vs 44.4%; OR 1.07, p=0.88); new diabetes was more frequent with simvastatin (4 vs 0).
RCTn = 85
Guilabert et al. Simvastatin in the prevention of recurrent pancreatitis: a triple-blinded randomised clinical trial (the SIMBA trial)